Table 3.
Clinicopathological characteristics of patients stratified by post-CRT LCR
| Characteristic | LCR low (n = 24) |
LCR high (n = 24) |
P value |
|---|---|---|---|
| Age (years) | 67 ± 13 | 64 ± 9 | 0.36 |
| Gender (male/female) | 17/7 | 15/9 | 0.54 |
| WBC (/μL) | 5391 ± 1652 | 4441 ± 1127 | 0.06 |
| TLC (/μL) | 730 ± 460 | 971 ± 347 | < 0.05 |
| Alb (mg/dL) | 3.4 ± 0.5 | 3.9 ± 0.4 | 0.91 |
| CRP (mg/dL) | 1.10 ± 1.60 | 0.26 ± 0.71 | < 0.05 |
| Pre-CRT LCR | 9006 ± 9368 | 23322 ± 13945 | < 0.05 |
| Tumor characteristic | |||
| Differentiation (tub1/tub2/other) | 9/14/1 | 10/13/1 | 0.41 |
| CEA (</≥ 5 ng/mL) | 18/6 | 16/8 | 0.53 |
| CA19-9 (</≥ 37 IU/mL) | 20/4 | 20/4 | 1.00 |
| Pre-CRT stage (I/II/II) | 1/3/15 | 2/8/13 | 0.20 |
| Treatment | |||
| Chemotherapy (S-1/UFT/5FU) | 12/9/3 | 17/2/5 | 0.05 |
| Surgery (LAR/ISR/APR/local) | 9/3/11/1 | 9/7/7/1 | 0.47 |
| Pathological response (grade 2/≥ 2) | 16/8 | 16/8 | 1.00 |
WBC white blood cell, TLC total lymphocyte count, Alb albumin, CRP C-reactive protein, CEA carcinoembryonic antigen, LCR lymphocyte-CRP ratio, tub1 well-differentiated tubular adenocarcinoma, tub2 moderately differentiated tubular adenocarcinoma, S-1 tegafur-gimeracil-oteracil, UFT tegafur-uracil, 5-FU 5-fluorouracil, CRT chemo-radiotherapy, LAR low anterior resection, ISR intersphincteric resection, APR abdominoperineal resection